Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Anticancer Research|December 8, 2020
Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal CancerMichio Kimura, Eiseki Usami, Tomoaki Yoshimura
Cureus|November 8, 2024
Short-Term Efficacy and Safety of Suvorexant and Lemborexant: A Retrospective StudyKoki Mori, Michio Kimura, Eiseki Usami
Anticancer Research|March 6, 2020
Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal CancerMichio Kimura, Eiseki Usami, Hitomi Teramachi, et al.
Cureus|April 9, 2024
Vancomycin-Induced Neutropenia With Subsequent Perioperative Readministration: A Case ReportYasutaka Shinoda, Teppei Kawabata, Kengo Ohashi, et al.
Oncology Letters|January 3, 2022
Elucidation of optimal proteinuria management based on the risk of ramucirumab-induced proteinuriaMichio Kimura, Eiseki Usami, Hitomi Teramachi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 14, 2025
Evaluation of the usefulness of protocol-based magnesium supplementation for hypomagnesemia in patients with advanced or recurrent colorectal cancer treated with panitumumabDaisuke Ito, Hiroki Asano, Michio Kimura, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 25, 2017
Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancerMichio Kimura, Eiseki Usami, Hitomi Teramachi, et al.
Molecular and Clinical Oncology|February 18, 2020
A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinomaMichio Kimura, Eiseki Usami, Hitomi Teramachi, et al.
Anticancer Research|June 4, 2021
Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal CancerMichio Kimura, Eiseki Usami, Hitomi Teramachi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 21, 2025
[Risk Benefit of Single Vial Multiple Use(DVO)Using Anti-Cancer Drug Preparation Robot-DVO Drug Selection Aimed at Both Improving Operational Efficiency and Reducing Medical Costs]Akihiro Moriya, Hiroki Asano, Michio Kimura, et al.
Pageof 7